Eli Lilly
Page 4 of 7
HealthNorth Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
By Simone Foxman, Madison Muller and BloombergJanuary 27, 2024
By Susanne Barton and BloombergJanuary 8, 2024
HealthEli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of for diabetes and obesity
By Alexa MikhailJanuary 4, 2024
NewslettersCareer advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company
By Sheryl EstradaDecember 4, 2023
HealthPfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
By Madison Muller and BloombergDecember 1, 2023
HealthWegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs
By Prarthana PrakashNovember 27, 2023
RetailScientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports
By Prarthana PrakashNovember 13, 2023
HealthFDA approves yet another weight loss drug to compete against blockbuster sellers Ozempic and Wegovy
By Madison Muller and BloombergNovember 8, 2023
HealthNovo Nordisk isn’t alone: Sales of Ozempic rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze
By Prarthana PrakashNovember 3, 2023
HealthNew weight-loss blockbuster drug emerges from study showing Mounjaro helps people lose 25% of their body weight or 60 pounds on average
By Jonel Aleccia and The Associated PressOctober 15, 2023
TechTikTok’s hidden ‘Ozempic economy,’ where weight-loss influencers trade referrals for drug discounts and cash
By Alexandra SternlichtSeptember 19, 2023
HealthBlockbuster weight loss drugs Ozempic and Wegovy cost Americans up to 10 times more than what other countries pay, research shows
By Christiaan HetznerAugust 18, 2023
By Jane ThierJune 24, 2023
By The Associated PressMay 3, 2023
Most Popular
